Skip to main content

REVIEW article

Front. Immunol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1459502
This article is part of the Research Topic Use of Big Data and Artificial Intelligence in Multiple Sclerosis View all 3 articles

Big data and artificial intelligence applied to blood and CSF fluid biomarkers in multiple sclerosis

Provisionally accepted
Georgina Arrambide Georgina Arrambide *Manuel Comabella Manuel Comabella Carmen Tur Carmen Tur *
  • Center for Multiple Sclerosis of Catalonia, Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain

The final, formatted version of the article will be published soon.

    Artificial intelligence (AI) has meant a turning point in data analysis, allowing predictions of unseen outcomes with precedented levels of accuracy. In multiple sclerosis (MS), a chronic inflammatory-demyelinating condition of the central nervous system with a complex pathogenesis and potentially devastating consequences, AI-based models have shown promising preliminary results, especially when using neuroimaging data as model input or predictor variables. The application of AI-based methodologies to serum/blood and CSF biomarkers has been less explored, according to the literature, despite its great potential. In this review, we aimed to investigate and summarise the recent advances in AI methods applied to body fluid biomarkers in MS, highlighting the key features of the most representative studies, while illustrating their limitations and future directions.

    Keywords: Multiple scleorsis (MS), Fluid biomarkers, Demyelinating, machine learning and AI, deep learning

    Received: 04 Jul 2024; Accepted: 30 Sep 2024.

    Copyright: © 2024 Arrambide, Comabella and Tur. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Georgina Arrambide, Center for Multiple Sclerosis of Catalonia, Vall d'Hebron University Hospital, Barcelona, 08035, Catalonia, Spain
    Carmen Tur, Center for Multiple Sclerosis of Catalonia, Vall d'Hebron University Hospital, Barcelona, 08035, Catalonia, Spain

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.